Literature DB >> 7775366

Breastfeeding and sertraline: a 24-hour analysis.

L L Altshuler1, V K Burt, M McMullen, V Hendrick.   

Abstract

BACKGROUND: Few reports exist on the levels of antidepressants in breast milk or on observed behavioral effects, if any, of neonates who are breast-fed. Thus, a dilemma exists for women who would like to breast-feed but require psychotropic medications.
METHOD: Analysis of sertraline levels was performed on eight samples of breast milk obtained over a 24-hour period, after 3 weeks of breastfeeding, from a lactating patient taking sertraline and nortriptyline. During this same 24-hour period, two serum samples each were taken from mother and child for analysis of sertraline and nortriptyline levels. After 7 weeks of exclusive breastfeeding, an additional serum sample was obtained from mother and child for analysis of sertraline levels. Drug metabolites were not measured.
RESULTS: Breast milk levels of sertraline were lowest 1 hour before the ingestion of sertraline and highest 5 to 9 hours after ingestion of the drug. The infant's serum sertraline and nortriptyline levels were nondetectable.
CONCLUSION: These data indicate that sertraline levels in breast milk vary substantially over 24 hours and appear to be lowest within the 2 hours before and 1 hour after ingestion of the medication, with the peak probably occurring between Hours 1 and 9 postingestion. However, the absence of detectable serum sertraline and nortriptyline levels in the infant suggests that if either medication is present in infant serum, its concentration would be extremely low. No abnormal occurrences have been noted in the development of the infant. It would be important in future studies to measure metabolites in addition to medication levels since the former have been associated with untoward events in an infant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7775366

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Antidepressants and breast-feeding: a review of the literature.

Authors:  S Dodd; A Buist; T R Norman
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 3.  Etiology and treatment of postpartum depression.

Authors:  Deborah Lynne Flores; Victoria C Hendrick
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

Review 4.  Neonatal exposure to drugs in breast milk.

Authors:  Patrick J McNamara; Maggie Abbassi
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

Review 5.  Use of contemporary antidepressants during breastfeeding: a proposal for a specific safety index.

Authors:  Salvatore Gentile
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 6.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

Review 7.  Sertraline and breastfeeding: review and meta-analysis.

Authors:  Emily Pinheiro; Debra L Bogen; Denada Hoxha; Jody D Ciolino; Katherine L Wisner
Journal:  Arch Womens Ment Health       Date:  2015-01-15       Impact factor: 3.633

Review 8.  Benefits and risks to mother and infant of drug treatment for postnatal depression.

Authors:  Shaila Misri; Xanthoula Kostaras
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 9.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

10.  Distribution and excretion of sertraline and N-desmethylsertraline in human milk.

Authors:  J H Kristensen; K F Ilett; L J Dusci; L P Hackett; P Yapp; R E Wojnar-Horton; M J Roberts; M Paech
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.